The mRNA-1083 generated an equivalent or better immunological response compared to current flu vaccines, matching GSK’s Fluarix Quadrivalent in adults aged 50 to 64 and outperforming Sanofi’s ...

Table II. Immunogenicity criteria for adults, set by the Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products. For the vaccine to be ...